Neuropeptide PACAP Protects the Retina from Diabetes Damage in Rats

Diabetes was induced in Wistar rats with streptozotocin injection. PACAP (100 pmol) was injected directly into one eye three times during the last week of a 3-week period. Retinas were analyzed using histology, immunohistochemistry (single/double labeling and whole-mount), quantitative RT-PCR, and Western blotting to assess structural and molecular changes.

Diabetic retinopathy is the leading cause of blindness in working-age adults, and current treatments focus on late-stage vascular damage. This study shows that PACAP can protect retinal neurons early in the disease process — before the blood vessel problems become severe. If neuropeptide-based therapies could be developed for the retina, they might preserve vision by preventing the neuronal damage that precedes and accompanies diabetic retinopathy.

Most diabetic retinopathy treatments target blood vessel leakage and abnormal vessel growth — the late-stage vascular problems. But researchers increasingly recognize that retinal neurons start dying early in diabetes, before obvious vascular changes. PACAP represents a neuroprotective strategy that could complement existing treatments by preserving the neurons themselves. This fits into a broader research movement toward treating the neural (not just vascular) component of diabetic eye disease.

This was a short-term (3-week) rat model of diabetes, which doesn't fully replicate the years-long progression of human diabetic retinopathy. Intravitreal injection is invasive and the study didn't test less invasive delivery methods. Specific quantitative data on cell counts and protein levels are in the full paper but not the abstract. No functional vision testing was reported.